Headache

Papers
(The H4-Index of Headache is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Anxiety, depression, and headache‐related disability in a large pediatric clinic–based sample135
Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment98
Facial variant of epicrania fugax secondary to a cerebellopontine angle meningioma83
Pilot study evaluating treatment with sumatriptan for moderate to severe post‐traumatic headache: A phase 2 open‐label study58
A retrospective analysis of the use of candesartan for migraine prevention in adolescents56
Migraine and peripheral pain models show differential alterations in neuronal complexity45
Erratum45
Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study40
Evidence for increased background neural noise in migraine with aura: Hyperactive but not hyperresponsive38
Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions38
Virtual issue: Education in headache medicine: Insights and advancements from 2023 to 202435
Effect of caffeine and caffeine cessation on cerebrovascular reactivity in patients with migraine33
Migraine treatment in pregnancy: A survey of comfort and treatment practices of women's healthcare providers31
Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine31
Migraine screening in English and Spanish31
Normal glymphatic system function in patients with new daily persistent headache using diffusion tensor image analysis along the perivascular space30
Characteristics associated with response to subcutaneously administered anti‐CGRP monoclonal antibody medications in a real‐world community cohort of persons living with migraine: A retrospective clin30
A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine30
Drug‐resistant epicrania fugax: Responding to onabotulinumtoxinA30
Popping the balloon: Abrupt onset of a spinal CSF leak and spontaneous intracranial hypotension in idiopathic intracranial hypertension, a case report29
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine29
Neuromodulation for primary headache disorders: Advantages and challenges27
Sequential administration of peripheral nerve blocks and  onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A ret26
Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐bl26
Index26
A retrospective review of sex differences of white matter hyperintensities in brain MRI of patients with migraine26
Developing and delivering a migraine disparities and diagnosis undergraduate medical educational program to underrepresented in medicine medical student members of the Student National Medical Associa26
0.22003293037415